Ovatodiolide Targets β-Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. (26th May 2013)
- Record Type:
- Journal Article
- Title:
- Ovatodiolide Targets β-Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. (26th May 2013)
- Main Title:
- Ovatodiolide Targets β-Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma
- Authors:
- Ho, Jar-Yi
Hsu, Ren-Jun
Wu, Chieh-Lin
Chang, Wen-Liang
Cha, Tai-Lung
Yu, Dah-Shyong
Yu, Cheng-Ping - Other Names:
- Chuang Shuang-En Academic Editor.
- Abstract:
- Abstract : Dysregulated β -catenin signaling is intricately involved in renal cell carcinoma (RCC) carcinogenesis and progression. Determining potential β -catenin signaling inhibitors would be helpful in ameliorating drug resistance in advanced or metastatic RCC. Screening for β -catenin signaling inhibitors involved in silico inquiry of the PubChem Bioactivity database followed by TCF/LEF reporter assay. The biological effects of ovatodiolide were evaluated in 4 RCC cell lines in vitro and 2 RCC cell lines in a mouse xenograft model. The synergistic effects of ovatodiolide and sorafenib or sunitinib were examined in 2 TKI-resistant RCC cell lines. Ovatodiolide, a pure compound of Anisomeles indica, inhibited β -catenin signaling and reduced RCC cell viability, survival, migration/invasion, and in vitro cell or in vivo mouse tumorigenicity. Cytotoxicity was significantly reduced in a normal kidney epithelial cell line with the treatment. Ovatodiolide reduced phosphorylated β -catenin (S552) that inhibited β -catenin nuclear translocation. Moreover, ovatodiolide decreased β -catenin stability and impaired the association of β -catenin and transcription factor 4. Ovatodiolide combined with sorafenib or sunitinib overcame drug resistance in TKI-resistant RCC cells. Ovatodiolide may be a potent β -catenin signaling inhibitor, with synergistic effects with sorafenib or sunitinib, and therefore, a useful candidate for improving RCC therapy.
- Is Part Of:
- Evidence-based complementary and alternative medicine. Volume 2013(2013)
- Journal:
- Evidence-based complementary and alternative medicine
- Issue:
- Volume 2013(2013)
- Issue Display:
- Volume 2013, Issue 2013 (2013)
- Year:
- 2013
- Volume:
- 2013
- Issue:
- 2013
- Issue Sort Value:
- 2013-2013-2013-0000
- Page Start:
- Page End:
- Publication Date:
- 2013-05-26
- Subjects:
- Alternative medicine -- Periodicals
615.505 - Journal URLs:
- http://ecam.oupjournals.org ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/241/ ↗
http://www.hindawi.com/journals/ecam/ ↗ - DOI:
- 10.1155/2013/161628 ↗
- Languages:
- English
- ISSNs:
- 1741-427X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3831.036630
British Library HMNTS - ELD Digital store - Ingest File:
- 17563.xml